BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

They could perhaps see sustained runs beyond this year.

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer, aiming to compare the drug against current standard chemotherapy ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting ...